Estrella Immunopharma (ESLA) announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected Artemis T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lymphomas. The second cohort will evaluate EB103 at a higher dose level following a review of safety data from the first dose cohort. As previously announced, no dose-limiting toxicities or treatment-related serious adverse events were observed in the first cohort. The initiation of dosing in the second cohort reflects steady progress in Estrella’s mission to complete Phase I of STARLIGHT-1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue